BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37819154)

  • 1. Immunotherapy for myelodysplastic syndrome and acute myeloid leukemia: where do we stand?
    Spillane DR; Assouline S
    Expert Rev Hematol; 2023; 16(11):819-834. PubMed ID: 37819154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BITES and CARS and checkpoints, oh my! Updates regarding immunotherapy for myeloid malignancies from the 2018 annual ASH meeting.
    Przespolewski AC; Griffiths EA
    Blood Rev; 2020 Sep; 43():100654. PubMed ID: 32029263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice.
    Masarova L; Kantarjian H; Ravandi F; Sharma P; Garcia-Manero G; Daver N
    Adv Exp Med Biol; 2018; 995():97-116. PubMed ID: 30539507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
    Liu Y; Bewersdorf JP; Stahl M; Zeidan AM
    Blood Rev; 2019 Mar; 34():67-83. PubMed ID: 30553527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel immune directed therapies in myelodysplastic syndromes and acute myeloid leukemia.
    Brunner AM
    Curr Opin Hematol; 2023 Mar; 30(2):38-44. PubMed ID: 36728945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
    Masarova L; Kantarjian H; Garcia-Mannero G; Ravandi F; Sharma P; Daver N
    Adv Exp Med Biol; 2017; 995():73-95. PubMed ID: 28321813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome.
    Arellano-Ballestero H; Sabry M; Lowdell MW
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid Leukemia.
    Haddad F; Zeidan AM; Daver N
    Cancer J; 2022 Jan-Feb 01; 28(1):43-50. PubMed ID: 35072373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Immunotherapy for Acute Myeloid Leukemia.
    Tabata R; Chi S; Yuda J; Minami Y
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Gallazzi M; Ucciero MAM; Faraci DG; Mahmoud AM; Al Essa W; Gaidano G; Mouhssine S; Crisà E
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia.
    Kapoor S; Champion G; Basu A; Mariampillai A; Olnes MJ
    Cancers (Basel); 2021 Oct; 13(19):. PubMed ID: 34638510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
    Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
    Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging role of immune checkpoint based approaches in AML and MDS.
    Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
    Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer cell (NK) subsets and NK-like T-cell populations in acute myeloid leukemias and myelodysplastic syndromes.
    Aggarwal N; Swerdlow SH; TenEyck SP; Boyiadzis M; Felgar RE
    Cytometry B Clin Cytom; 2016 Jul; 90(4):349-57. PubMed ID: 26648320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute myeloid leukemia and myelodysplastic syndrome associated with a combination of immune checkpoint inhibitor and platinum-based chemotherapy.
    Nakatsuru K; Tsubouchi K; Hirahata M; Nakashima T; Takahata Y; Okamatsu Y; Shiraishi Y; Okamoto I; Harada T
    Thorac Cancer; 2023 Aug; 14(22):2225-2228. PubMed ID: 37337950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Abaza Y; Zeidan AM
    Cells; 2022 Jul; 11(14):. PubMed ID: 35883692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelodysplastic syndrome and immunotherapy novel to next in-line treatments.
    Linder K; Lulla P
    Hum Vaccin Immunother; 2021 Aug; 17(8):2602-2616. PubMed ID: 33941042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.
    Hattori N; Nakamaki T
    Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.
    Zhao A; Zhao M; Qian W; Liang A; Li P; Liu H
    Front Immunol; 2022; 13():1063986. PubMed ID: 36713414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive cell therapy for acute myeloid leukemia.
    Ma H; Padmanabhan Iyer S; Parmar S; Gong Y
    Leuk Lymphoma; 2019 Jun; 60(6):1370-1380. PubMed ID: 30628504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.